Machine learning-assisted prognosis prediction and surgical decision-making for glioblastoma: perceived benefits and concerns of patients, caregivers, and neurosurgeons - Takeaways - MDSpire

Machine learning-assisted prognosis prediction and surgical decision-making for glioblastoma: perceived benefits and concerns of patients, caregivers, and neurosurgeons

  • By

  • Meredith V. Parsons

  • Olivia Buckley

  • Hamasa Ebadi

  • Eric Leuthardt

  • Tristan McIntosh

  • July 2, 2026

  • 0 min

Share

  • 1

    Participants viewed machine learning (ML) models as beneficial for integrating extensive patient data to aid decision-making in glioblastoma treatment.

  • 2

    Concerns were raised about potential inaccuracies and biases in ML model outputs, as well as the risk of replacing clinical judgment.

  • 3

    Patients and caregivers expressed worries about the early development stage of ML models and their impact on patient hope and understanding.

  • 4

    The study emphasizes the importance of engaging multiple stakeholders to ensure responsible integration of ML in clinical decision-making.

  • 5

    Trust in ML-assisted decision-making is closely linked to patient trust in their physicians, particularly in palliative care contexts.

Original Source(s)

Machine learning-assisted prognosis prediction and surgical decision-making for glioblastoma: perceived benefits and concerns of patients, caregivers, and neurosurgeons

  • by Meredith V. Parsons, Olivia Buckley, Hamasa Ebadi, Eric Leuthardt, Tristan McIntosh

  • July 2, 2026

Related Content

Smartphones Spot Ocular Malignancies

Could a smartphone-based AI system bring ocular oncology screening directly into the patient’s home?

  • July 2, 2026

  • 3 min
ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

  • 1 min
The impact of abiraterone and enzalutamide on hypokalemia incidence in patients with prostate cancer: a systematic review and meta-analysis